Get the Stockscreener App
11.41
2.81%
-0.33
After Hours:
11.29
-0.12
-1.05%
Xencor Inc stock is traded at $11.41, with a volume of 487.37K.
It is down -2.81% in the last 24 hours and down -9.73% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$11.74
Open:
$11.8
24h Volume:
487.37K
Relative Volume:
0.70
Market Cap:
$814.79M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-3.9481
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
-1.55%
1M Performance:
-9.73%
6M Performance:
+51.93%
1Y Performance:
-27.74%
1-Day Range:
$11.14
$11.81
1-Week Range:
$11.12
$11.90
52-Week Range:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
11.41 | 838.36M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Earnings Beat: Is Xencor Inc stock showing strong momentumDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Big Money Moves: What is the Moat Score of Xencor Inc2025 Momentum Check & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug Swings: Can TACOU be recession proofTake Profit & Safe Capital Growth Stock Tips - baoquankhu1.vn
CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type - GlobeNewswire Inc.
Aug Movers: Is The Shyft Group Incs growth already priced inJuly 2025 Trade Ideas & Weekly High Conviction Ideas - baoquankhu1.vn
Understanding the Setup: (XNCR) and Scalable Risk - Stock Traders Daily
Will Xencor Inc. stock rally after Fed decisionsProfit Target & Consistent Growth Equity Picks - mfd.ru
Tech Rally: What hedge funds are buying Xencor Inc.2025 Macro Impact & AI Powered Market Entry Ideas - mfd.ru
Will Xencor Inc. stock go up in YEAR2025 Trade Ideas & AI Forecasted Entry and Exit Points - mfd.ru
Is Xencor Inc. affected by consumer sentimentJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - mfd.ru
The Truth About Xencor Inc: Why Biotech Degens Suddenly Care About XNCR - AD HOC NEWS
Meme Stocks: Is Xencor Inc a top pick in the sector2025 Market Outlook & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Reactions: Can Xencor Inc expand its profit margins2025 Major Catalysts & Accurate Trade Setup Notifications - baoquankhu1.vn
Xencor, Inc. (XNCR) Investor Outlook: A Biotech Stock With A 148% Potential Upside - DirectorsTalk Interviews
How do insiders feel about Xencor Inc.2025 Geopolitical Influence & Technical Entry and Exit Tips - mfd.ru
Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 28% Below Their Intrinsic Value Estimate - simplywall.st
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor (NASDAQ:XNCR) Stock Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
Can Xencor Inc. expand its profit margins2025 Top Gainers & Weekly Breakout Watchlists - mfd.ru
What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector - Yahoo Finance
EV Market: Does Xencor Inc stock reflect fundamentalsMarket Trend Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet? - 富途牛牛
The Technical Signals Behind (XNCR) That Institutions Follow - Stock Traders Daily
Truist Securities reiterates Buy rating on Xencor stock amid TL1A momentum - Investing.com Australia
Xencor (NASDAQ:XNCR) Stock Passes Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Bear Alert: Is Xencor Inc impacted by rising rates2025 Market Outlook & Safe Entry Point Identification - baoquankhu1.vn
Xencor’s Financial Runway Supports Ambitious Clinical Pipeline - AD HOC NEWS
Update Report: Can Xencor Inc stock outperform in a bear market2025 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Xencor, Inc. (XNCR) Stock Analysis: Unlocking a 132.90% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage - Finviz
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Precision Trading with Xencor Inc. (XNCR) Risk Zones - Stock Traders Daily
Contrasting NRx Pharmaceuticals (NASDAQ:NRXP) & Xencor (NASDAQ:XNCR) - Defense World
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know - sharewise.com
Xencor, Inc. (XNCR) Stock Analysis: A Biotech Contender With 119.93% Potential Upside - DirectorsTalk Interviews
Activity Recap: Is Xencor Inc impacted by rising ratesQuarterly Profit Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Could Early XmAb819 Signals Reshape Xencor’s (XNCR) Broader T‑Cell Engager Investment Narrative? - Yahoo Finance
Market Catalysts: What is the target price for Xencor Inc stockMarket Activity Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
SG Americas Securities LLC Takes Position in Xencor, Inc. $XNCR - Defense World
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor (XNCR) Valuation Check After New Oncology And Autoimmune Pipeline Milestones - Yahoo Finance
Navigating the Valuation Gap in Xencor Shares - AD HOC NEWS
Xencor (NASDAQ:XNCR) Shares Down 7.1%Here's Why - MarketBeat
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving Average – Time to Sell? - Defense World
Merger Talk: What hedge fund activity signals for Xencor Inc stockJuly 2025 Action & Accurate Intraday Trade Tips - Bộ Nội Vụ
Performance Recap: Can Xencor Inc stock outperform in a bear marketMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
ImmunityBio, Xencor Drugs Win E.U. Nods - labusinessjournal.com
Xencor's Clinical Milestone Paves Way for Potential Revaluation () - aktiencheck.de
How supply shortages influence Xencor Inc. (XE9) stockJuly 2025 Summary & High Accuracy Investment Entry Signals - Улправда
Xencor, Inc.Common Stock (NQ: XNCR - FinancialContent
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):